Market Overview

UPDATE: Aegis Capital Raises PT on Stemline Therapeutics Following Recent Progress

Share:
Related STML
Stemline Therapeutics Presents Clinical Update From Ongoing SL-401 Pivotal BPDCN Trial, Produced 86% Overall Response Rate
Stemline Reports Five Presentations, Will Offer Update on SL-401 Trial from Ongoing Pivotal BPDCN Trial at ASH Meeting

In a report published Friday, Aegis Capital analyst Raghuram Selvaraju reiterated a Buy rating on Stemline Therapeutics (NASDAQ: STML), and raised the price target from $35.00 to $40.00.

In the report, Aegis Capital noted, “Given the recent progress at Stemline Therapeutics and the fact that the company - following its most recent equity financing - now appears to be exceptionally well-funded, we are maintaining our Buy rating and instituting a 12-month price target of $40.00 per share vs. our original 18-month price target of $35.00 per share. The smallcap oncology sector continues to find favor among biotechnology-focused investors, and we anticipate that Stemline should continue to attract interest based on the accelerated development pathway for its lead drug candidate, SL-401, in blastic plasmacytoid dendritic cell neoplasm (BPDCN) and other hematological malignancies. We note that Stemline has thus far been the best-performing biotech IPO of 2013, and anticipate further outperformance going forward as the firm advances the development of multiple drug candidates simultaneously through the deployment of its strengthened cash resources.”

Stemline Therapeutics closed on Thursday at $25.43.

Latest Ratings for STML

DateFirmActionFromTo
Apr 2015H.C. WainwrightInitiates Coverage onBuy
Apr 2015JefferiesMaintainsBuy
May 2014JefferiesMaintainsBuy

View More Analyst Ratings for STML
View the Latest Analyst Ratings

Posted-In: Aegis Capital Raghuram SelvarajuAnalyst Color Price Target Analyst Ratings

 

Related Articles (STML)

View Comments and Join the Discussion!